Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.49 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16299781 | 0.96 | MGLL (0.59) | PRSS1PRSS2PRSS3MGLLALDH1A1 | |
| SCHEMBL16299753 | 0.92 | PRSS1 (0.64) | PRSS1PRSS2PRSS3DGKAFAAH | |
| SCHEMBL16299767 | 0.92 | PRSS1 (0.64) | PRSS1PRSS2PRSS3DGKAFAAH | |
| SCHEMBL25247276 | 0.86 | DGKA (0.69) | MGLLDGKAFAAHALDH1A1MAPT | |
| SCHEMBL25246800 | 0.86 | DGKA (0.69) | MGLLDGKAFAAHALDH1A1MAPT | |
| SCHEMBL25249563 | 0.86 | DGKA (0.69) | MGLLDGKAFAAHALDH1A1MAPT | |
| SCHEMBL25298415 | 0.86 | DGKA (0.69) | MGLLDGKAFAAHALDH1A1MAPT | |
| SCHEMBL25288167 | 0.86 | DGKA (0.69) | MGLLDGKAFAAHALDH1A1MAPT | |
| SCHEMBL25287675 | 0.86 | DGKA (0.69) | MGLLDGKAFAAHALDH1A1MAPT | |
| SCHEMBL25246317 | 0.86 | DGKA (0.69) | MGLLDGKAFAAHALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8962580-B2 | Chemical modifications of monomers and oligonucleotides with cycloaddition | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962580-B2 | Chemical modifications of monomers and oligonucleotides with cycloaddition | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | PRSS1 4276/4885PRSS2 4392/4885PRSS3 4270/4885 |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | PRSS1 4276/4885PRSS2 4392/4885PRSS3 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.